ArticleJournal of molecular and cellular cardiology plus2026
Selective ROCK2 inhibition reduces microvascular obstruction but does not reduce myocardial infarction after ischaemia and reperfusion.
Article in Journal of molecular and cellular cardiology plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myocardial ischaemia/reperfusion (I/R) injury causes infarction, microvascular obstruction (MVO), and haemorrhage. MVO, often driven by vasospasm, lacks effective therapy. The non-selective ROCK inhibitor fasudil, used for cerebral vasospasm, limits infarct size after myocardial I/R, but the roles of individual ROCK isoforms in limiting infarction and MVO remain unclear. Aims: To determine the contribution of ROCK2 to myocardial and microvascular obstruction and to assess the vasodilatory potential of ROCK2 inhibition. Methods: ROCK1/2 expression was analysed in rat hearts by RNAscope. Vascular myography assessed arterial responses to ROCK inhibitors. Rats underwent 30 min coronary occlusion and 180 min reperfusion, with ROCK2 inhibitor KD025 (100 mg/kg i.p.) or vehicle administered before reperfusion. Infarct size (%AAR) and MVO (%AAR) were quantified by TTC and Thioflavin S staining, respectively. Infarct size was also compared in WT and ROCK2 Results: ROCK2 mRNA was more highly expressed than ROCK1 in both myocardium and coronary vasculature. The dual ROCK1/2 inhibitor, fasudil (10 mg/kg), reduced infarct size (34.5 ± 5.7 vs 55.8 ± 4.7%, P = 0.02, n = 6), whereas the ROCK2-selective KD025 (100 mg/kg) had no effect (43.7 ± 5.5 vs 48.3 ± 4.9%, P = 0.87, n = 8) and also showed no vasodilation ex vivo. ROCK2 Conclusion: Dual ROCK1/2 inhibition protects myocardium from I/R injury, whereas selective ROCK2 inhibition or deficiency does not, implicating ROCK1 in infarct limitation. In contrast, ROCK2 inhibition reduced MVO, identifying ROCK2 as a potential microvascular target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.